Leidos Awarded DARPA Contract to Develop Advanced Protective Equipment for U.S. Military

Rhea-AI Summary

Leidos has secured a prime contract from DARPA for the Personalized Protective Biosystem program, aimed at enhancing defense against chemical and biological threats. This five-year, cost-plus-fixed-fee contract has a total ceiling value of $19.3 million. The project will develop lightweight protective equipment through an initiative called SPIDERMAN, which aims to provide effective defense without prior knowledge of the agents used. The program addresses the urgent need for adaptive personal protection highlighted by recent global health challenges.

Positive

• Awarded a $19.3 million contract from DARPA for the PPB program.
• Development of SPIDERMAN technology for lightweight protective gear.
• Addresses urgent military and healthcare needs for better protective equipment.
• Leidos leads a world-class team for innovative personal protection solutions.

Negative

• None.

RESTON, Va., Sept. 29, 2021 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE^® 500 science and technology leader, was recently awarded a prime contract by Defense Advanced Research Projects Agency (DARPA) for their Personalized Protective Biosystem (PPB) program. Through this award, Leidos will develop technology that reduces the need for burdensome protective equipment while increasing defense against both existing and future chemical and biological (CB) threats. This three-phase, five-year cost-plus-fixed-fee contract has a total ceiling value of $19.3 million.

"Leidos thrives at tackling the world's toughest challenges; in this case, protecting frontline personnel against emerging threats with a revolutionary approach to personal protection equipment," said Leidos Chief Technology Officer Jim Carlini.

DARPA's PPB program addresses the national need for lightweight and adaptive personal protection equipment for military and healthcare personnel. The recent pandemic highlighted this challenge on a global scale.

Through this award, Leidos is launching a combination of innovative, robust and flexible platforms known as SPIDERMAN (Smart Protective Integrated Dynamic Ensemble for Reactive, Multifaceted Agent Neutralization). The technology comes in the form of both lightweight protective materials and tissue-protective countermeasures. It enables CB threat protection without prior knowledge of the agent's nature. The goal is to create new and improved ways to address different, emerging and uncharacterized threats through advanced technology.

"Leidos has assembled a world-class team and is proud to lead the execution of this revolutionary program," said Dr. John Dresios, Executive Biology Director and Principal Investigator for the Leidos PPB team. "SPIDERMAN has the potential to deliver transformative advancements that will provide broad and specific, as well as rapid and sustainable protection against chemical and biological threats. We're excited to help engineer new ways to protect the military and our nation." 

About Leidos
Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil, and health markets. The company's 43,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $12.30 billion for the fiscal year ended January 1, 2021. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 1, 2021, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact:             

Melissa Dueñas
(571) 526-6850
Melissa.L.Duenas@leidos.com

Thomas Doheny
(571) 474-4735
Dohenyt@leidos.com

Alyssa Pettus
(571) 992-5499
Alyssa.T.Pettus@leidos.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-awarded-darpa-contract-to-develop-advanced-protective-equipment-for-us-military-301387503.html

SOURCE Leidos Holdings, Inc.

FAQ

What contract did Leidos receive from DARPA on September 29, 2021?

Leidos was awarded a prime contract for the Personalized Protective Biosystem (PPB) program.

What is the value of the contract Leidos received for the PPB program?

The total ceiling value of the contract is $19.3 million.

What technology is Leidos developing under the PPB program?

Leidos is developing the SPIDERMAN technology, which focuses on lightweight protective materials for defense against chemical and biological threats.

How long is the contract awarded to Leidos by DARPA?

The contract spans five years and is structured as a cost-plus-fixed-fee arrangement.

What urgent need does the PPB program address according to Leidos?

The program addresses the need for lightweight and adaptive personal protection equipment for military and healthcare personnel.